A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.

Styczynski, J; Tallamy, B; Waxman, I; van de Ven, C; Milone, M C; Shaw, L M; Harrison, L; Morris, E; Satwani, P; Bhatia, M; George, D; Bradley, M B; Garvin, J H; Schwartz, J; Baxter-Lowe, L A; Cairo, M S

Styczynski, J; Tallamy, B; Waxman, I; van de Ven, C; Milone, M C; Shaw, L M; Harrison, L; Morris, E; Satwani, P; Bhatia, M; George, D; Bradley, M B; Garvin, J H; Schwartz, J; Baxter-Lowe, L A; Cairo, M S.

Affiliation

Styczynski J; Department of Pediatric Hematology and Oncology, Collegium Medicum UMK, Bydgoszcz, Poland.

Bone Marrow Transplant ; 46(6): 790-9, 2011 Jun.

Article in En | MEDLINE | ID: mdl-20818441

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Hematopoietic Stem Cell Transplantation / Transplantation Conditioning Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2011 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google